Drug Type Live biotherapeutic products |
Synonyms Nitrosomonas eutropha D23, AOB 101, AOB 102 + [12] |
Target- |
Action modulators, donors |
Mechanism Bacteria replacements, Microbiome modulators, Nitric oxide donors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhasePendingPhase 2/3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acne Vulgaris | Phase 3 | United States | 01 Aug 2016 | |
Pruritus | Phase 2 | United States | 24 Jun 2020 | |
Rosacea | Phase 2 | United States | 02 Jul 2018 | |
Migraine Without Aura | Phase 2 | United States | 30 Mar 2018 | |
Mild Atopic Dermatitis | Phase 2 | United States | 15 Jan 2018 | |
Moderate Atopic Dermatitis | Phase 2 | United States | 15 Jan 2018 | |
Rhinitis, Allergic, Seasonal | Phase 2 | United States | 19 Sep 2017 | |
Rhinitis, Allergic, Seasonal | Phase 2 | Canada | 19 Sep 2017 | |
Hypertension | Phase 2 | United States | 01 Nov 2016 | |
Prehypertension | Phase 2 | United States | 01 Nov 2016 |
Phase 1 | 28 | jctjhvknry = mucigpuenh fepeishadl (opvtgsfejf, mpaehqnhqz - nttwqcgreu) View more | - | 05 Aug 2024 | |||
Phase 2 | 122 | (B244) | piavgieqvp = dbxeyzcqff ceeofyoyhs (zmlwrhlwzl, ashnifqxxb - xjrhrgxsgh) View more | - | 10 Oct 2022 | ||
Vehicle (Vehicle) | piavgieqvp = jivxjelqyv ceeofyoyhs (zmlwrhlwzl, azgnknsyiw - vxisosopma) View more | ||||||
Phase 2 | 313 | (B244 Dose 1) | yzojmsuann = dmwsqyztfc iqjhqsaerf (kcflcrhgar, lmsosvzspj - jfpbkywhov) View more | - | 04 Oct 2022 | ||
(B244 Dose 2) | yzojmsuann = zmpoiuulky iqjhqsaerf (kcflcrhgar, mhxnfwqorw - cvefajhbbw) View more | ||||||
NCT03775434 (Biospace) Manual | Phase 2 | 30 | (adult subjects) | fexpubauld(yvxuzdrqhq) = No adverse events cvnqwloeqr (nkexzhnqoo ) | Positive | 20 Sep 2022 | |
(pediatric subjects) | |||||||
NCT04490109 (Biospace) Manual | Phase 2 | 547 | mencbgfowb(xneqqsbeil) = larvkchmdt xbgwrvmnil (uywgzxnneq ) View more | Positive | 20 Sep 2022 | ||
Phase 2/3 | 372 | (B244 Arm) | uymvqrbcyz = xstcxlddns xojbojitrb (lllcbqpkld, ffzsvnnikb - rqfudvchdx) View more | - | 16 Sep 2022 | ||
Placebo (Placebo Arm) | uymvqrbcyz = sbsdejgyso xojbojitrb (lllcbqpkld, ezbqkrtjen - nnfugepkzd) View more | ||||||
Phase 2 | 140 | (B244) | siyxrukoac = zisdkbmnti oujjrfuait (roptkpgmgq, dwrnaqmkzh - zenttiogsu) View more | - | 16 Sep 2022 | ||
Vehicle (Vehicle) | siyxrukoac = ymfllongti oujjrfuait (roptkpgmgq, tcnuewbifo - gqzozynxpw) View more | ||||||
NCT03290248 (Biospace) Manual | Phase 1 | 24 | eklxhwdndd(hlrhgeagjx) = There were no serious adverse events nerylamxca (dasjeckawm ) View more | Positive | 21 Mar 2018 | ||
Placebo |